TOKYO, Feb 2 (Reuters) - Astellas Pharma Inc (4503.T), Japan’s second-largest drugmaker, said on Monday it was not considering a hostile bid for CV Therapeutics Inc CVTX.O and its offer price was the best one.
Astellas last week said it had offered to buy all shares in CV Therapeutics, a U.S. biotechnology firm, for $16 each or $1 billion in total. [ID:nN27436060]
CV Therapeutics, which had already rejected the offer, announced later the extension of a shareholder rights plan to counter Astellas’ bid. [ID:nBNG379272] (Reporting by Yumiko Nishitani)